+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Protein Kinase C Epsilon Type - Pipeline Review, H2 2020

  • ID: 5229511
  • Drug Pipelines
  • November 2020
  • Region: Global
  • 60 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • BryoLogyx Inc
  • CHS Pharma Inc
  • Neurotrope Bioscience Inc
  • VM Discovery Inc
  • Young Therapeutics LLC
  • MORE
Summary

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Protein kinase C (PKC) is an enzyme belonging to a family of serine- and threonine-specific protein kinases that is activated by calcium and the second messenger diacylglycerol. This kinase showed involvement in many different cellular functions, such as neuron channel activation, apoptosis, cardioprotection from ischemia, heat shock response, as well as insulin exocytosis.

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 9 molecules. The molecules developed by companies in Phase II and Preclinical stages are 1 and 8 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Genetic Disorders, Infectious Disease, Oncology and Ophthalmology which include indications Alzheimer's Disease, Traumatic Brain Injury, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alcohol Addiction, Depression, Dry (Atrophic) Macular Degeneration, Fragile X Syndrome, Human Immunodeficiency Virus (HIV) Infections (AIDS), Ischemia Reperfusion Injury, Ischemic Stroke, Lymphoma, Multiple Sclerosis, Neurology, Parkinson's Disease, Rett Syndrome and Stroke.

The latest report Protein Kinase C Epsilon Type - Pipeline Review, H2 2020, outlays comprehensive information on the Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)
  • The report reviews Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • BryoLogyx Inc
  • CHS Pharma Inc
  • Neurotrope Bioscience Inc
  • VM Discovery Inc
  • Young Therapeutics LLC
  • MORE
Introduction

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Overview

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Companies Involved in Therapeutics Development
  • BryoLogyx Inc
  • CHS Pharma Inc
  • Neurotrope Bioscience Inc
  • VM Discovery Inc
  • Young Therapeutics LLC
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Drug Profiles

Bryostatin-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Activate Epsilon PKC for Ischemic Stroke - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Activate PKC Epsilon for Neurology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Activate PRKCE for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecules to Inhibit PRKCE for HIV and Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
sulindac - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
VMD-2202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
YT-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Dormant Products
Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Discontinued Products

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 13, 2020: BryoLogyx announces completion of world’s first GMP synthesis of bryostatin-1
  • Oct 07, 2020: Neurotrope begins Phase II trial of Alzheimer's drug candidate
  • Aug 04, 2020: BryoLogyx announces cooperative research and development agreement for Bryostatin-1 with National Cancer Institute
  • Jul 30, 2020: Neurotrope Bioscience announces agreement with worldwide clinical trials, to conduct ongoing phase 2 study of Bryostatin-1, partially funded by NIH, for Alzheimer's Disease
  • Jun 10, 2020: Neurotrope announces strategic partnership with BryoLogyx for supply of synthetic Bryostatin-1 and continuation of the National Cancer Institute (NCI) trial for childhood leukemia
  • May 28, 2020: Neurotrope launches new long-term clinical trial of Bryostatin with the National Institutes of Health for the treatment of patients with Alzheimer's Disease
  • Jan 22, 2020: Neurotrope provides corporate update after completing Bryostatin-1 data analysis for advanced Alzheimer's disease trial
  • Sep 10, 2019: Neurotrope Alzheimer’s Phase II trial fails to meet endpoints
  • Aug 13, 2019: Neurotrope announces publication highlighting the potential of bryostatin as a unique neurorestorative therapy
  • Jul 15, 2019: Neurotrope concludes data collection in confirmatory phase 2 clinical trial of moderately severe to severe Alzheimer's Disease
  • Jul 11, 2019: Neurotrope to present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented
  • Jun 03, 2019: Neurotrope's president and chief scientific officer to present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019
  • Mar 21, 2019: Neurotrope CEO statement on development of Bryostatin
  • Mar 14, 2019: Neurotrope doses last patient in Alzheimer’s trial
  • Dec 17, 2018: Neurotrope announces publication of phase 2 study of Bryostatin-1 in moderate to severe alzheimer's disease in the Journal of Alzheimer's Disease
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indication, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by BryoLogyx Inc, H2 2020
  • Pipeline by CHS Pharma Inc, H2 2020
  • Pipeline by Neurotrope Bioscience Inc, H2 2020
  • Pipeline by VM Discovery Inc, H2 2020
  • Pipeline by Young Therapeutics LLC, H2 2020
  • Dormant Projects, H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
3 of 3
  • BryoLogyx Inc
  • CHS Pharma Inc
  • Neurotrope Bioscience Inc
  • VM Discovery Inc
  • Young Therapeutics LLC
Note: Product cover images may vary from those shown
Adroll
adroll